HER2 being the oncogene of BC, its overexpression is reported in about 20% of primary BC, which is proved to increase the cancer stem cells’ population via PTEN/Akt/mTORC1 signaling and is associated with poor clinical outcomes [23,24]. This evidence concerns the gene AKT1 and breast cancer.